11 studies found for:    weill | Open Studies | "Esophageal Neoplasms"
Show Display Options
Rank Status Study
1 Unknown  Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
Conditions: Esophageal Cancer;   Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Interventions: Drug: Azacitidine;   Drug: Oxaliplatin;   Drug: Epirubicin;   Drug: Capecitabine
2 Recruiting Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders
Conditions: Ampullary Cancer;   Duodenal Cancer;   Bile Duct Cancer;   Bile Duct Disorders;   Gallstones;   Obstructive Jaundice;   Pancreatic Disorders (Noncancerous);   Colorectal Cancer;   Esophageal Cancer;   Barrett's Esophagus;   Gastric Malignancies;   Pancreatic Cancer;   Pediatric Gastroenterology;   Cholangiocarcinoma;   Pancreatic Pseudocysts;   Acute and Chronic Pancreatitis;   Recurrent Pancreatitis;   Cholangitis;   Bile Leak;   Biliary Strictures;   Pancreatic Divisum;   Biliary and Pancreatic Stones;   Choledocholithiasis
Intervention:
3 Recruiting 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Conditions: Kidney Cancer;   Head and Neck Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Esophageal Cancer;   Gliomas
Intervention: Drug: 177Lu-J591
4 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Carcinoma Breast Stage IV;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Urinary Bladder Neoplasms;   Cervical Cancer;   Endometrial Cancer;   Follicular Thyroid Cancer;   Glioblastoma Multiforme
Intervention: Drug: IMMU-132
5 Recruiting FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Gastric Adenocarcinoma;   Gastric Cancer
Interventions: Procedure: FDG-PET;   Procedure: surgery;   Drug: 5-FU;   Drug: capecitabine;   Drug: docetaxel;   Drug: Irinotecan;   Radiation: 3D-CRT;   Radiation: IMRT
6 Recruiting Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Conditions: Gastroesophageal Junction Adenocarcinoma;   Gastric Cancer
Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin;   Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
7 Recruiting Comparing the Efficacy of Endoscopic FNA vs FNB in Diagnosing Solid Gastrointestinal Lesions
Conditions: Pancreatic Tumor;   Gastric Tumor;   Esophageal Tumor;   Lymphadenopathy;   Duodenal Tumor
Intervention: Procedure: Endoscopic ultrasound guided needle tissue acquisition.
8 Recruiting A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
Conditions: Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma
Interventions: Drug: Ramucirumab;   Drug: Paclitaxel
9 Recruiting A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
Conditions: Metastatic Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma
Interventions: Drug: Ramucirumab;   Drug: Capecitabine;   Drug: Cisplatin;   Drug: Placebo;   Drug: Fluorouracil
10 Recruiting GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Condition: Gastric Adenocarcinoma
Interventions: Drug: GS-5745;   Drug: GS-5745 Placebo;   Drug: Leucovorin;   Drug: 5-fluorouracil;   Drug: Oxaliplatin
11 Recruiting EndoMAXX EVT Compared to EndoMAXX
Condition: Malignant Esophageal Strictures
Interventions: Device: EndoMAXX EVT;   Device: EndoMAXX

Indicates status has not been verified in more than two years